Latest studies
Every paper our editors flag with a plain-language note and an evidence rating. Filter by evidence, species, or design to find what actually applies to you.
- Study · RetatrutideMixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
This is an analytical chemistry paper, not a clinical study, so it says nothing about efficacy or safety. Its practical significance is quality verification: a validated, high-accuracy method covering approved and pipeline GLP-1 agonists in one run is directly useful for authenticating products in a market where counterfeit and compounded GLP-1 formulations are a live concern. The validation metrics reported are solid for the class, though independent replication in other labs is the usual next step. Relevant to readers who follow product-testing and vendor-credibility questions rather than clinical outcomes.
Journal of chromatography. An=——Oct 11, 2026 - Study · RetatrutideSupported
Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice.
A genuinely useful comparative design — same models, same readouts, three agents — and the pathway dissection (PI3K-AKT for semaglutide, PI3K-AKT plus PPAR for tirzepatide, PI3K-AKT plus NF-kB for retatrutide) gives mechanism rather than just an endpoint. The limits are the usual ones: mouse ureteral-obstruction and ageing models are aggressive surrogates for human chronic kidney disease, and a single dose level per agent cannot establish that retatrutide is more potent in people. The authors frame it as hypothesis-generating, which is the right register. Retatrutide remains investigational and unapproved.
iSciencen=—AnimalSep 18, 2026 - Study · RetatrutideSupported
CARDIOVASCULAR EFFECTS OF INCRETIN RECEPTOR AGONISTS: BEYOND GLYCEMIC CONTROL.
A narrative review, but one that assembles genuinely current material: SUMMIT cardiac-MRI data showing reverse ventricular remodelling with tirzepatide, and isolated human atrial tissue work showing direct inotropic effects of retatrutide. The retatrutide cardiovascular story remains surrogate-only until TRIUMPH outcome data report, which the authors acknowledge. A useful synthesis of the mechanism-beyond-glycemia argument.
Canadian journal of physiology and pharmacologyn=——Sep 10, 2026 - Study · RetatrutideSupported
Pharmacological management of obesity: Current landscape and emerging therapies.
A serviceable landscape review rather than new data. Its value is the pipeline framing: the cagrilintide-semaglutide combination and retatrutide are positioned as the agents expected to narrow the efficacy gap with bariatric surgery, while oral and longer-acting formulations are the adherence play. The regional guideline detail is a reminder that staging conventions and access differ considerably by market. Claims about approaching surgical efficacy rest on trial weight-loss percentages, not on head-to-head outcome data.
Indian journal of pharmacologyn=——Sep 1, 2026 - Study · RetatrutideMixed
Incretin-based therapies in diabetic kidney disease: toward integrated cardio-kidney-metabolic disease modification.
The evidence gradient is the point worth carrying away: semaglutide has a dedicated hard-outcome kidney trial behind it, while the kidney case for tirzepatide and retatrutide currently rests on weight and metabolic endpoints plus mechanistic reasoning. This is a narrative review from a national study group, so it reflects a considered clinical position rather than a systematic quantitative synthesis, and the mechanistic sections lean on translational work that has not been confirmed in humans. Readers following the newer co-agonists should note that renal benefit is anticipated, not yet demonstrated.
Kidney research and clinical practicen=——Sep 1, 2026 - Study · RetatrutideSupported
Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.
An Annals of Internal Medicine update with declared funding of none, adding 14 new randomised trials and roughly 11,000 participants to the prior version - about as authoritative a synthesis as this field currently has. The key limitation is stated plainly by the authors: heterogeneity ruled out pooled quantitative synthesis, so the percentage figures come from individual trials rather than a single meta-analytic estimate and should not be lined up as a strict ranking. Safety reporting across trials was inconsistent, which matters most for the newest multiagonists where exposure is still short.
Annals of internal medicinen=——Sep 1, 2026 - Study · RetatrutideMixed
Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia.
Retatrutide is not approved anywhere, which means every vial sold under that name comes from the grey market — and independent testing of what those vials contain is exactly the kind of evidence this beat lacks. This team has previously documented mislabeled and inaccurately dosed peptide products in Australia's unregulated supply. The abstract is not yet available, so we are noting the paper now and will report the composition findings once we can review the full text.
Drug and alcohol reviewn=——Sep 1, 2026 - Study · RetatrutideSupported
Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.
Post hoc biomarker analyses of phase 2 trials are exploratory by construction, though the false-discovery-rate correction and the use of two independent trials strengthen the picture. The magnitude of the apolipoprotein B and triglyceride-rich particle reductions is what stands out, since those measures track cardiovascular risk more closely than LDL cholesterol alone. The split inflammation result between the diabetes and non-diabetes cohorts is unexplained and worth flagging; none of this substitutes for the outcome trials still ahead for the triple agonist.
Diabetes, obesity & metabolismn=—HumanAug 17, 2026 - Study · RetatrutideMixed
Integrating GLP-1 Receptor Agonists Into Dermatology Practice: Safety and Monitoring Strategies.
Useful consolidation of the dermatologic side-effect picture for the GLP-1 class, written for practicing dermatologists but readable as a map of what to watch for. The headline items — alopecia, eruptions, facial volume loss — are drawn from associations of varying strength, and the authors are careful to label the rarer signals as emerging rather than established. A solid reference piece as this drug class moves further into cosmetic and skin-adjacent territory.
Clinics in dermatologyn=——Aug 6, 2026 - Study · RetatrutideMixed
The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity.
A tidy reference review of incretin pharmacology from a veteran of the drug-mechanism literature. The most useful sections for our readers explain the molecular engineering behind long-acting peptides — fatty acid acylation piggybacking on albumin — and lay out the current approval map, with retatrutide still in trials. Nothing new here, but a well-organized primer on how this drug class actually works.
Pharmacological researchn=——Aug 5, 2026 - Study · RetatrutideWeak / none
Retatrutide effects on diabetic rats' cognition.
An animal study reporting on retatrutide's effects on cognition in a diabetic rat model. No abstract detail is available, and rodent findings are early-stage evidence that requires human study before any clinical inference.
Lab animaln=—AnimalAug 1, 2026 - Study · RetatrutideSupported
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
This is a major, GRADE-rated network meta-analysis — 262 RCTs, 99,791 participants, 19 drugs — and it puts both tracked peptides at the center of the obesity-pharmacotherapy map. With moderate-to-high certainty, tirzepatide showed the largest one-year weight loss (−14.9% vs lifestyle), with subcutaneous and oral semaglutide also substantial (−9.8% and −10.9%). Crucially, subcutaneous semaglutide was the only drug associated with reduced all-cause mortality and myocardial infarction, and both semaglutide and tirzepatide were associated with lower heart-failure risk — though the mortality/MI estimates are driven by cardiovascular-outcome trials in high-risk populations, an important scoping caveat. The analysis is admirably balanced on harms: larger weight loss generally came with more discontinuation and gastrointestinal events, and tirzepatide, while cutting fat mass most (−25.7%), also cut lean mass most (−8.3%) — a real signal on muscle loss. No drug meaningfully improved quality of life. This is high-quality synthesis and among the most useful single references for weighting these peptides. Read the benefit and harm columns together.
BMJ (Clinical research ed.)n=—HumanJul 8, 2026 - Study · RetatrutideWeak / none
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats.
This is a single animal study in a streptozotocin diabetic rat model, so findings are preliminary and not directly applicable to humans. Retatrutide was associated with partial attenuation of memory deficits and lower hippocampal TNF-alpha, though not full normalization. The authors note direct brain exposure was not established and call for further work.
Behavioural brain researchn=—AnimalJul 1, 2026 - Study · RetatrutideSupported
Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
This meta-analysis pools randomized controlled trials, giving it relatively strong evidentiary weight for retatrutide's cardiometabolic effects. It reports consistent reductions in blood pressure and atherogenic lipids, with heterogeneity noted for cholesterol outcomes. Findings are association-based from a drug still under clinical development.
High blood pressure & cardiovascular preventionn=—HumanJun 29, 2026 - Study · RetatrutideSupported
Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
A living systematic review and network meta-analysis for the American College of Physicians, and one of the strongest evidence syntheses in this batch: 69 randomised controlled trials, 112,511 participants, with 37 trials at low risk of bias. Network meta-analysis lets researchers rank treatments partly through indirect comparison, useful when head-to-head trials are scarce, but indirect estimates carry more uncertainty than direct ones. Researchers reported that nearly all drugs beat placebo or lifestyle intervention for weight loss while causing more adverse-event discontinuations; that semaglutide probably reduced mortality and major cardiovascular events; and that semaglutide and tirzepatide produced the greatest weight loss in both pairwise and network analyses. Crucially, the authors flagged that evidence for mortality, cardiovascular events and serious adverse events was limited and direct head-to-head data sparse, so the weight-loss ranking is far more certain than the hard-outcome claims. Weight this as high-quality comparative evidence for weight change, and more cautiously for survival and cardiovascular benefit.
Annals of internal medicinen=—HumanJun 16, 2026 - Study · RetatrutideSupported
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.
This is a large phase 3 double-blind randomized controlled trial, the strongest tier of clinical evidence for retatrutide in type 2 diabetes. All three doses were associated with significantly greater HbA1c and weight reductions versus placebo, and the safety profile matched other GLP-1-class agents. Two deaths occurred, both reported as unrelated to the study drug; the trial was funded by the manufacturer.
Lancetn=—HumanJun 13, 2026 - Study · RetatrutideWeak / none
Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models.
This is a preclinical study in diet-induced obese mouse and hamster models, so results are early and not human data. Retatrutide was associated with marked weight loss, lower HOMA-IR, and reduced hepatic triglycerides, though it did not improve liver histopathology scores. The work primarily validates the models for testing obesity and MASH therapies.
Obesity (Silver Spring, Md.)n=—AnimalJun 1, 2026 - Study · RetatrutideWeak / none
GIPR:GCGR co-agonism restores normal weight in obese rodents.
This is preclinical rodent research where retatrutide serves as a benchmark comparator to a new GLP-1-sparing co-agonist. It offers a mechanistic signal that weight reduction can occur without GLP-1 activity, potentially reducing gastrointestinal effects, but findings are animal-only and early. Retatrutide is central to the comparison rather than the novel agent tested.
Molecular metabolismn=—AnimalJun 1, 2026 - Study · SemaglutideWeak / none
Do GLP-1 Receptor Agonists Sabotage Fat Grafts? A Scoping Review of GLP-1 Receptor Agonist Effects on Adipocyte Biology and Implications for Autologous Fat Transfer.
This scoping review maps mechanistic reasons GLP-1-class drugs might interfere with autologous fat grafting, but the authors stress no clinical or preclinical studies have directly examined this outcome. The conclusions are explicitly hypothesis-generating rather than evidence-based. Retatrutide is mentioned partly in the context of off-label bodybuilding use.
Aesthetic surgery journaln=——Jun 1, 2026